Skip to main content

Table 4 Comparison of CR rate among genotypes after two courses of Ara-C based chemotherapy

From: Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients

Genotype

Total (n)

CR (n, %)

Non-CR (n, %)

OR (95% CI)

p

OR (95% CI)a

pa

rs4082155

 AA

157

96 (61.1%)

61 (38.9%)

1.00 (reference)

 

1.00 (reference)

 

 AG

266

184 (69.2%)

82 (30.8%)

0.701 (0.464–1.060)

0.092

0.562 (0.340–0.931)

0.025*

 GG

123

88 (71.5%)

35 (28.5%)

0.626 (0.377–1.039)

0.07

0.501 (0.265–0.946)

0.033*

 AA

157

96 (61.1%)

61 (38.9%)

1.00 (reference)

 

1.00 (reference)

 

 AG + GG

389

272 (69.9%)

117 (30.1%)

0.677 (0.460–0.997)

0.048*

0.544 (0.338–0.876)

0.012*

rs6767907

 GG

237

155 (65.4%)

82 (34.6%)

1.00 (reference)

 

1.00 (reference)

 

 GA

242

171 (70.7%)

71 (29.3%)

0.698 (0.396–1.230)

0.213

0.668 (0.323–1.379)

0.275

 AA

67

42 (62.7%)

25 (37.3%)

0.889 (0.506–1.560)

0.681

1.126 (0.548–2.317)

0.746

rs76208147

 CC

422

273 (64.7%)

149 (35.3%)

1.00 (reference)

 

1.00 (reference)

 

 CT

110

84 (76.4%)

26 (23.6%)

0.567 (0.350–0.919)

0.021*

0.600 (0.342–1.053)

0.075

 TT

14

11 (78.6%)

3 (21.2%)

0.500 (0.137–1.819)

0.293

0.545 (0.114–2.604)

0.447

  1. *p < 0.05
  2. a Adjusted for age, risk stratification, LDH and WBC